The wireless motility capsule (WMC) is an ambulatory noninvasive and nonradioactive diagnostic sensor that continuously samples intraluminal pH, temperature, and pressure as it moves through the gastrointestinal (GI) tract. This review summarizes the data obtained in clinical trials with the WMC and discusses its role in clinical practice. The United States Food and Drug Administration has approved the SmartPill GI monitoring system for the evaluation of gastric emptying time in patients with suspected gastroparesis, the evaluation of colonic transit time in patients with suspected chronic constipation, and for the characterization of pressure profiles from the antrum and duodenum. Clinical studies have shown that WMC-measured GI transit times can distinguish patients with motility abnormalities similarly to conventional testing. However, the WMC offers the advantage of providing a full GI-tract profile, enabling the detection of multiregional GI transit abnormalities in patients with suspected upper or lower GI dysmotility. The WMC also characterizes pressure profiles of the GI tract and impaired pressure profile limits are reported for the antrum and duodenum. In comparison with manometry, interpretations of pressure measurements obtained by the WMC are limited by an inability to detect a peristaltic pressure wave front, and further investigation is required to develop clinical applications. Clinical studies with the WMC indicated that it should be considered for the evaluation of regional and whole gut transit time in patients with suspected upper or lower dysmotility, particularly if there are concerns about multiregional dysmotility.
Introduction
Functional gastrointestinal (GI) disorders such as functional dyspepsia, chronic constipation, and irritable bowel syndrome are multifactorial in eti ology and can include an association with visceral hypersensitivity or dysmotility of the GI tract. After evaluating for alarm conditions and failure of empiric therapy, motility testing is often rec ommended, which has traditionally been focused on the specific region of the GI tract consistent with the chief complaint [Abell et al. 2008; Rao, 2009; Sarosiek et al. 2010 ]. However, studies show a significant overlap between functional motility disorders of the upper and lower GI tract, for example, patients with slow transit constipa tion were found to have delayed gastric emptying and abnormal functioning of the esophageal body and sphincters [Hasler, 2007; Agrawal et al. 2009] . A comprehensive assessment of upper and lower GI motility can provide critical objective data to aid in diagnosis and the planning of opti mal therapeutic and feeding strategies.
The wireless motility capsule (WMC) provides a method of measuring regional and whole gut transit time in a single standardized ambulatory test without radiation. Sensors housed within the WMC continuously measure pH, pressure, and temperature for up to 5 days after ingestion as the WMC moves through the GI tract to provide transit and pressure information. Current meth ods for the assessment of GI tract function routinely involve radiation, are mostly limited to one GI tract region assessment, require multiple tests, and are often not available in a standardized protocol.
The American and European Neurogastroen terology and Motility Societies have recommended WMC testing in the assessment of: (a) gastric emptying and regional and whole gut transit time in individuals with suspected gastroparesis, symp toms of upper GI dysmotility, or suspected altera tions of GI motility in multiple regions; (b) small bowel transit time (SBTT) and for clinical use in facilitating detection of small bowel dysfunction in patients with generalized motility disorders; (c) assessment of colonic transit time (CTT) in subjects with symptoms of chronic constipation while providing measurements of regional and whole gut transit . The United States Food and Drug Administration (FDA) approved the SmartPill GI Monitoring System for: (a) the evaluation of gastric emptying time in patients with suspected gastroparesis; (b) the evalu ation of CTT in patients with suspected slow transit constipation; (c) measurement of pH, tem perature, and pressure throughout the GI tract with characterization of pressure profiles from the antrum and duodenum [FDA, 2009] . The aim of this review is to summarize objective data accumu lated from WMC clinical trials, and to discuss the role of WMC testing in clinical GI practice.
Description of the test
Description of the WMC The WMC system (SmartPill Corporation, Buffalo, NY, USA) consists of an ingestible sin gleuse capsule, a receiver, and display software. Both the capsule and receiver have a battery life rated for 5 days of use once activated. The indigestible capsule measures 26 mm × 13 mm and houses sensors for pH, temperature, and pressure. The pH measurement is accurate to 0.5 pH units and pressure measurement is accu rate to +/-5 mmHg below 100 mmHg [SmartPill Corporation, 2009] .
Wireless motility capsule test
The test starts with the ingestion of a meal to ini tiate the postprandial motility pattern following an overnight fast. The meal consists of a standard ized egg sandwich (255 kcal, 2% fat, 1 g fiber), or the nutritionally equivalent SmartBar (260 kcal, 2% fat, 2 g fiber), followed by 120 ml water [Kuo et al. 2008] . Immediately after the meal, the patients swallow the WMC with 50 ml water. Patients are then released from the clinical setting once absence of any complications from the inges tion is confirmed. They are given the data receiver and a diary for recording bowel movements, food intake, sleep, and GI symptoms. Physical restric tions include no strenuous activities such as sit ups, abdominal crunches, and prolonged aerobic activity (> 15 min), which can affect pressure measurements. Additionally, patients refrain from alcohol, smoking, and the use of GI medications that could affect motility.
Patients are asked to fast for 6 h after capsule ingestion, after which they ingest a 250 ml Ensure® meal (250 kcal, protein 9 g, carbohy drates 40 g, fat 6 g, fiber 0 g) (Abbott Laboratories, Abbott Park, Il, USA). This meal allows for the evaluation of the fed response, which is the change in contractile pattern of the small bowel from a fasting to postprandial pattern. On WMC tracings, the fed response manifests as an increase in contraction frequency and/or average ampli tude [Brun et al. 2010] . Patients are then instructed to resume their regular diet and rou tine 2 h after ingestion of the Ensure meal, and to return the data receiver and diary to the medical facility after 5 days. Downloaded data are analyzed using the display software (MotiliGI, SmartPill Corporation).
Motility measurements by WMC
Transit time/anatomical landmarks pH, temperature, and pressure are used to define anatomic landmarks for measuring regional gut transit time. Capsule ingestion is marked by an abrupt rise in the temperature profile. Gastric emptying time (GET) is defined as the time from ingestion of the WMC to the abrupt pH rise (> 3 pH units) from gastric baseline to a pH > 4, marking the passage of the capsule from the acidic antrum to the alkaline duodenum [Mojaverian et al. 1985 [Mojaverian et al. , 1989 Evans et al. 1988; Miner et al. 2003 ]. The ileocecal junction (ICJ) is defined as the abrupt pH drop of at least 1 pH unit, observed at least 30 min after GET and persist ing for a minimum of 10 min [Zarate et al. 2010; Evans et al. 1988 ]. Body exit time is usually seen as a significant temperature drop when the ambient environmental temperature is sensed rather than body temperature ( Figure 1 ). Compared with conventional GI transit time tests, the WMC has the advantage of being ambu latory, noninvasive, standardized, more widely available, and with less radiation exposure.
Pressure
The WMC also measures intraluminal pressure, functioning as a freefloating single pressure sensor device that records and transmits the amplitude and frequency of contractions to pro duce a standardized pressure profile characteri zation. The pressure data provide the following contractility measurements: frequency of contrac tions (Ct), amplitude of contractions, presented as an absolute value or area under the curve (AUC), and motility index (MI), which is calcu lated as MI = Ln(sum of amplitudes × number of contractions + 1). Normal contractility reference values have been published for the stomach and proximal small bowel [Kloetzer et al. 2010 ]. The WMC cannot detect peristaltic wave propagation and this remains a major limitation until new standards are developed to aid in the identification of various motility patterns.
Stomach
Transit times. Gastric emptying scintigraphy (GES) is the current most commonly used method for measuring stomach transit time due to its ease of quantification and the use of physi ologic test meals. The test is widely available and directly measures the emptying of a physiological meal, but is limited by variability in methodology, particularly the length of the study and meal type. In addition, adoption of consensus guide lines remains limited primarily to tertiary centers [Abell et al. 2008] . It does represent the most physiologic method for measuring the gastric emptying of a meal. Gastric emptying breath testing is another viable option, but is not avail able for clinical use in the USA.
The WMC offers an alternative method to meas ure gastric emptying, albeit providing an indirect rather than direct measure of meal emptying due to the indigestible nature of WMC. The relationship of WMC emptying to meal emptying is based on a predictable sequence of physiologic motor events that include meal trituration and emptying followed by gastric housekeeping activities to remove indigestible meal remnants and objects such as the WMC [Guyton and Hall, 2010] .
The relationship of the emptying of a meal to the emptying of WMC was studied by Kuo and colleagues who reported a strong correlation of r = 0.73 between the two events [Kuo et al. 2008 ]. Cassilly and colleagues studied the sequence and mechanism of emptying WMC compared with a meal from the stomach by recording simultaneously WMC, GES, and antroduodenal manometry (ADM) in healthy volunteers. On average, the WMC emptied from the stomach after 96.6% of the meal moved postpyloric. The authors reported a strong correlation of the WMC gastric residence time to the duration of a fed pattern on manometry (r = 0.813; p < 0.01) [Cassilly et al. 2008 ]. Further investigation with simultaneous WMC testing and ADM in diseased patients such as those with gastroparesis would be helpful in further clarifying the utility of the WMC in the diseased state.
The diagnostic utility of WMC compared with GES to distinguish healthy from gastroparetic patients was reported by Kuo and colleagues. Simultaneous comparisons were made between WMC GET and GES using the Pearson correla tion coefficient as a measure of agreement in a study comparing 87 healthy patients and 61 gas troparetics. The gastroparetics were defined by both a history of typical gastroparesis symptoms and a documented delayed scintigraphy test within the past 2 years. Receiver operator characteristic curve profiles for the two measures were equiva lent (AUC(GET) = 0.83 versus AUC(GES) = 0.82) and, as noted above, a strong correlation of WMC GET to GES at 4 h was observed (Table 1 ) [Kuo et al. 2008 ].
Of note, 65% of the symptomatic subjects dem onstrated a delay by GET while 44% demon strated a delay by GES. The Tougas 4 h cutoff, defined as gastric emptying < 90% of the meal emptied at 4 h, was used for scintigraphy. This cutoff is defined by the 95th percentile in a healthy subject cohort [Tougas et al. 2000 ]. The WMC used a cutoff point of 5 h to mark delayed gastric emptying based on an analysis of the dataset from Kuo and colleagues providing val ues for sensitivity and specificity of 0.65 and 0.87, respectively [Kuo et al. 2008] . The increased detection of delayed emptying by WMC may be due to the fact that WMC GET reflects the function of the fasted state in addition to the fed state, whereas gastric scintigraphy typically meas ures fed state emptying only. It is worth noting that some normal transit results observed in gastroparetics with GES may be due to variabil ity in gastric emptying with time, especially in idiopathic gastroparesis.
Pressure. ADM is the current standard in mea suring gastric and small intestinal pressure and contractility. An ADM device has six or more pressure transducers spaced at fixed locations along a catheter. This allows for simultaneous recording of pressure waves at multiple sites and detection of peristaltic wave propagation. Its util ity is limited by the invasive nature of the test, the expertise required to perform and interpret the test, and its lack of availability in most clinical settings.
The WMC provides a standardized gastric pres sureprofile characterization, though the clinical utility requires further refinement. Kloetzer and colleagues used the WMC to compare antroduo denal pressure profiles, using Ct, AUC, and MI, between 71 healthy and 42 gastroparetic subjects (Table 2) [Kloetzer et al. 2010] . Overall, gastro paretics had a 35% reduction in Ct in both the gastric and small bowel windows compared with healthy subjects. In diabetic subjects with gastroparesis, the Ct was reduced by 50%. Furthermore, 33% of the gastroparetic subjects had gastric motor function below the fifth percen tile of the normal population. This prevalence increased to 73% for subjects with a very delayed GET > 12 h [Kloetzer et al. 2010] . One hypothe sis is that significantly lower pressure parameters in patients with severely delayed GET may be an indicator of an inability to generate effective high [Michalek et al. 2011] . They also noted that the frequency of gastric contractions measured by the WMC during the hour prior to gastric emptying is doubled regardless of acid suppression therapy. This doubling in contraction frequency, the persistence of the pH increase as the WMC moves into the small bowel, and the lack of temperature and pH change in response to further meal ingestion serve as additional markers in determining GET in those who need to remain on acid suppression therapy or have unclear pH data. Additional research is required to evaluate the utility of the WMC in other hypoacidic states such as achlorhydria. The WMC can identify SBTT with its ability to define gastric emptying and ileocecal transit based on changes in pH profile [Michalek et al. 2011; Zarate et al. 2010] . SBTT is marked by the cap sule entering the duodenum from the antrum until the WMC passes through the ICJ. A study by Maqbool and colleagues compared SBTT val ues obtained from whole gut scintigraphy with WMC SBTT in 10 healthy individuals and found significant correlation (r = 0.69; p = 0.05) [Maqbool et al. 2009 ].
The mean SBTT of WMC is 4.1 h based on test ing in 87 healthy volunteers. The normal limits for SBTT defined by the 5th and 95th percentile are 2.5-6 h [Brun et al. 2011a] . The same report also retrospectively reviewed WMC data from 77 patients with suspected GI dysmotility at a single center over a 3year period. They found that 29 (37.6%) patients presenting with symptoms of upper or lower motility disorders had a slow SBTT compared with controls with respective means of 447 min versus 301 min (p < 0.001) [Brun et al. 2011a ]. The clinical significance of SBTT and its correlation with symptoms requires further investigation.
Pressure. Unlike SBTT, evaluation of small bowel contractility by ADM is more established. ADM is clinically useful, particularly in the assessment of gastroparesis and differentiating between myopathy and neuropathy, but as dis cussed earlier has limitations. n = 26 p = 0.07 p = 0.23 p = 0.09 p = 0.14 p = 0.88 p = 0.21 Diabetic gastroparetics 37 3032 10.84 62 4325 11.6 n = 16 p = 0.04 p = 0.26 p = 0.03 p = 0.02 p = 0.55 p = 0.04
Adapted from Kloetzer et al. [2010] . AUC, area under the curve; Ct, frequency of contractions; MI, motility index.
The clinical utility of WMC to differentiate myo pathic from neuropathic small bowel disorders is now only being explored. Urma and colleagues first reported the observation of a fed response in the small bowel pressure profile in healthy subjects [Urma et al. 2005 ]. Brun and colleagues recently noted this fed response was delayed in patients with gastroparesis, and blunted and shorter in patients with constipation [Brun et al. 2010 ]. These findings may suggest an underlying neuropathy contributing to postprandial symptoms.
Preliminary data also showed that patients found to have delayed SBTT also had significantly lower proximal small bowel pressure parameters of mean contractions (p = 0.003), mean AUC (p = 0.025), and MI (p < 0.001), compared with healthy individuals [Brun et al. 2011a ]. Additional investigation is needed to determine the clinical significance of these findings.
Colon
Transit time. Evaluating CTT is key in the eval uation of chronic constipation. Methods include whole gut scintigraphy, which has the advantage of being able to assess segmental transit time, but is hindered by its limited availability, expense, and use of radiation [Lundin et al. 2007 ]. Radi opaque marker (ROM) tests are the most widely used to evaluate CTT, but inherent limitations include the need for serial Xrays, multiple visits, radiation exposure, and lack of standardization [Rao, 2005; Rao et al. 2009 ].
The WMC has been demonstrated to be compara ble to ROM in the evaluation of CTT [Camilleri et al. 2010] . In a study of 78 constipated and 87 healthy subjects, the simplified or Hinton ROM test and the WMC were simultaneously adminis tered to compare the sensitivity, specificity, and AUC or receiver operating characteristic curve of each technique. Constipated subjects had a signifi cantly slower day 2 and day 5 ROM and WMC transits than the controls (p < 0.001) with a good correlation of CTT of the WMC to the number of ROMs remaining (Table 3 ). Furthermore, the WMC had comparable specificity (0.95) and sen sitivity (0.46) to ROM for identifying abnormal transit time in patients with constipation symp toms (Table 4 ) ].
The upper limit of normal colonic transit defined in the Rao study ] above (95th percentile of the normal population) was validated by Camilleri and colleagues in their prospective study comparing CTT by WMC and ROM, using the procedure described by Metcalf and colleagues in 157 chronically constipated patients [Camilleri et al. 2010; Metcalf et al. 1987] . For delayed tran sit, the positive percentage agreement between WMC and ROM was 79.6% (95% confidence interval (CI) = 0.67-0.98). The negative percent age agreement, representing normal transit, was 90.8% (95% CI = 0.83-0.96). Overall device agreement was 87%. There was a significant cor relation (p < 0.001) of CTT between ROMs and the WMC (r = 0.707) [Camilleri et al. 2010] .
Pressure. Colonic manometry is the conven tional method for evaluating colonic pressure and contractility, yet it has similar drawbacks to ADM, and requires a stool cleanout making it difficult to assess the colon under normal physiologic conditions [Scott, 2003; De Schryver et al. 2002] . The WMC can obtain colonic pressure profiles and does not require a colonic preparation. However, the clinical application of WMC pressure data has yet to be firmly established, and the use of WMC to relate characterized pressure profiles of the colon to diseased states does not yet have FDA approval. Adapted from Rao et al. [2009] . CI, confidence interval; ROM, radiopaque marker.
The most complete assessment of colonic pressure profiles characterized by WMC was reported by Hasler and colleagues in 53 healthy and 36 constipated subjects; 12 with the constipation subtype of irritable bowel syndrome (CIBS). Colonic pressure activity was found to be greater distally than proximally with the number of con tractions increasing from the first to fourth quar tiles in healthy patients (p < 0.0001), along with those with moderate slow transit constipation (p = 0.002), CIBS (p = 0.02), and normal transit constipation (p = 0.052). However, no differences were seen in pressure activity from the first to fourth quartile in patients with severe slow transit constipation. The authors considered that the greater contractile activity distally may serve a role in stool propulsion. The blunting of this increase in distal contractions may contribute to delayed colonic transit in those with severe slow transit constipation. The authors also noted ele vated pressure amplitudes in patients with CIBS ].
Safety of device
Through three multicenter clinical trials with 495 subjects involving healthy, gastroparetic (n = 61), or constipated (n = 269) subjects, there was one serious adverse event reported where the capsule failed to empty the stomach after 5 days in a gastroparetic patient. The capsule passed into the duodenum successfully with intravenous erythromycin. Endoscopic assessment showed the presence of a gelatinous bezoar in the patient's stomach. All the remaining subjects enrolled in clinical studies were able to pass the WMC in the stool with the majority occurring within 5 days of ingestion and the longest retention time being 26 days. An inability to swallow the capsule was uncommon with only 3 (0.6%) out of a total of 495 subjects unable to ingest the WMC. Equipment malfunction (capsule, receiver and/or software) was more common with 36 (7.2%) incidences of equipment or software malfunctions Camilleri et al. 2010 ]. This failure rate is likely to be secondary to the use of prototypic equipment in the earliest studies, which has since been upgraded. In a postmarket analysis of approximately 6000 WMC ingestions, the incidence of equipment failure was 0.8-0.9% [SmartPill Corporation, 2009 ].
Bowel obstruction secondary to capsule retention represents the most serious potential adverse event of WMC testing. The manufacturer reports a WMC retention rate of 0.33% based on 20 reports of prolonged capsule retention in a post market analysis of 6000 capsules. Prolonged retention was defined by radiologic identification of the WMC in the body 2 weeks postingestion on kidneys, ureters, and bladder (KUB) imaging. Of the 20 patients, 5 underwent endoscopic capsule retrieval from the stomach. In the remaining cases, the capsule was monitored radiologically and ultimately exited the body without interven tion. There were no surgical interventions associ ated with WMC retentions reported to date [SmartPill Corporation, 2009] .
Clinical guidelines for the management of WMC retention are based on anatomic location. Upon return of the data receiver, body exit of the cap sule can be confirmed by analyzing the tempera ture data. If unable to determine body exit, the location of the capsule (stomach, small bowel, or colon) can be determined using pH data. If the Adapted from Rao et al. [2009] . CI, confidence interval.
WMC is located in the stomach and small bowel, serial Xrays are indicated with potential endos copy or medical intervention with a prokinetic agent. If located in the colon, follow up beyond symptom monitoring is not recommended due to a low risk of obstruction and experience that suggests capsule passage will occur with routine constipation management.
Clinical applications
Evidence continues to mount that a significant portion of GI dysmotility is multiregional, as seen in patients with slow transit constipation who also have delayed transit by gastric or small bowel scintigraphy [Hasler, 2007] . While the clinical role of WMC pressure data requires more clinical investigation, transit time data from WMC offers a unique opportunity to assess the whole GI tract with one noninvasive ambulatory standardized test. The American and European Neurogastroenterology and Motility Societies reiterate this concept in their position paper on GI transit time stating that the WMC is recom mended for regional and whole gut transit time evaluation in individuals with upper GI symp toms, gastroparesis, small bowel dysfunction, constipation or colonic disorders, or in those with alterations of GI motility in multiple regions .
Several WMC studies have shown that many patients with symptoms of dysmotility in one GI region often have abnormalities in other regions.
Sarosiek and colleagues reported that both CTT (p = 0.005) and WGTT (p <0.001)
were significantly longer in patients with gastro paresis than in healthy controls [Sarosiek et al. 2010] . Similarly, a study by Rao and colleagues showed that in constipated patients not only was CTT (p < 0.0001) delayed compared with healthy controls, but GET (p = 0.0123) was also signifi cantly delayed . A recent study by Kuo and colleagues examining WMC measure ments in relation to clinical suspicion revealed that in patients with a clinical suspicion of gastro paresis, many also had delayed SBTT (20.4%) or CTT (53.2%). Conversely, patients with sus pected delayed CTT also had delayed GET (41.7%) or delayed SBTT (14.3%) (Table 5 ) ].
In the abovementioned retrospective analysis by Kuo and colleagues of 83 clinical patients referred to tertiary centers with suspected gas tric, small intestinal, or colonic transit dysmotil ity, abnormal transit was found in 68% of the cases with 35.1% showing generalized transit abnormalities in two or more regions (Figure 2) . The authors noted that WMC testing eliminated the need for gastric scintigraphy (17%), small bowel barium transit (54%), and colon ROMs (68%). The WMC findings led to new diagnoses in 53% of patients and significantly influenced management decisions in 67% of cases through modified nutritional regimens (14%), surgical referrals (6%), and new medications (60%). Examples of the latter include prescribing proki netics, such as metoclopramide, to patients with suspected slow transit constipation who were found to have delayed gastric emptying by WMC and using laxatives like PEG 3350 in patients with gastroparesis who were noted to have slow colonic transit [Kuoet al. 2011 ].
Rao and colleagues examined the diagnostic utility of the WMC in comparison to conven tional motility tests in patients with suspected upper and lower GI dysmotility who also had normal endoscopic evaluations. New diagnostic information was obtained with the WMC test in 53% of the lower GI (p = 0.006) and 47% of the upper GI group (p = 0.001), with 43% of the patients receiving new additional diagnoses after the WMC test. Often, the WMC test revealed GI transit anomalies in regions other than the suspected region. The WMC test led to changes in management plans in 30% of subjects in the lower GI group and 50% of subjects in the upper GI group. Treatment modifications included pre scriptions for laxatives, prokinetics, antiemetics, antidepressants, or nutritional and behavioral modifications. The WMC testing also guided further workup: a finding of normal CTT in a patient with constipation and difficulty with def ecation led to recommendations for anorectal manometry to assess for pelvic floor dysfunction ].
The complete GI tract profile offered by the WMC may provide a useful tool in the manage ment of a patient with severe constipation who is considering colectomy as a treatment option.
Over 18% of patients thought to be suffering solely from prolonged colon transit were found on evaluation to have gastroparesis as their dom inant motility disorder [Camilleri et al. 2010] .
In constipated patients with diffuse GI dysmotility, colectomy has a higher incidence of poor out comes. Out of 21 patients with colonic inertia who underwent total abdominal colectomy (TAC), 90% had a successful outcome in long term follow up, while only 13% of the 16 patients with generalized intestinal dysmotility had pro longed relief after TAC [Redmond et al. 1995] . The WMC is well suited for a full regional and whole gut transit time evaluation and may change management decisions confirming or avoiding surgery and reduce additional testing in this population.
Limitations
While the WMC provides a full GI tracttransit profile in a standardized protocol, the pressure profiles are limited by nonstationary, single point pressure measurements throughout the GI tract. As a new method of measuring GI Ct, new stand ards need to be developed and validated before the relevance of this information is clear. Encouraging results have been published regard ing the utility of these measurements: detecting decreased contraction frequency in the stomach in gastroparetics [Kloetzer et al. 2010 ]; observing a blunting of the small bowel fed response in gas troparetics [Brun et al. 2010] ; measuring abnor mal small bowel pressure parameters when both GES and GET were normal [Lee et al. 2009 ]; or distinguishing differences in regional Ct activity in constipated patients ]. The WMC, with only one pressure sensor, is unable to detect a pressure wave front, which limits its utility in comparison to traditional manometric testing. However, with the invasive nature and limited availability of manometry, the WMC may have significant potential as further investigation continues to evolve the clinical utility of WMC pressure data.
The WMC cannot distinguish the absolute time of emptying of a meal or distinguish between liquid and solid emptying; rather it measures the total meal emptying. Furthermore, the WMC measures gastric emptying indirectly through the use of a physiologic meal. Scintigraphy test ing leads to a more physiologic assessment of transit time.
As a nondigestible capsule that needs to be ingested, the WMC should not be administered to those patients with suspected strictures, fistu las, or GI obstructive symptoms. In addition, it should be used with caution for anyone with a history of gastric bezoars, dysphagia, or disor ders of swallowing, recent GI surgery, Crohn's disease, or diverticulitis.
Summary
The WMC is a novel technology offering a non invasive, nonradioactive, standardized method to assess intraluminal pH, temperature, and pres sure, allowing for the measurement of gastric, small bowel, colon, and whole GI transit times.
As a single ambulatory test, it allows for an assessment of isolated and diffuse motility transit abnormalities. Interpretation of Ct measurements obtained by the WMC is limited compared with manometry testing, but continues to evolve. The WMC should be considered by gastroenterolo gists to evaluate regional and whole gut transit time for patients with motility and functional GI disorders.
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